Lilly Targets Sanofi Diabetes Top-Seller on Weight Loss

Eli Lilly & Co. may have an edge in the $20 billion diabetes market with its novel drug that matches Sanofi’s top-seller Lantus at controlling blood sugar while helping patients lose weight.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.